Diclak tablets with prolonged release 75 mg No. 10 buy. Price from 70 ₽

Pharmacological properties of the drug Diklak

Diclofenac sodium (sodium salt of [2-(2,6-dichlorophenyl)-amino]-phenylacetic acid) is an NSAID from the group of phenylacetic acid derivatives, which has pronounced antirheumatic, antipyretic, analgesic and anti-inflammatory properties. The mechanism of action is due to inhibition of the biosynthesis of prostaglandins, kinins and other mediators of pain and inflammation, a decrease in capillary permeability, and a stabilizing effect on lysosomal membranes. Inhibits platelet aggregation induced by adenosine diphosphate and collagen. in vitro experiments , at concentrations equivalent to those achieved when treating patients, it does not inhibit the biosynthesis of cartilage tissue proteoglycans. After oral administration of enteric tablets, diclofenac sodium is quickly and completely absorbed from the intestine. The maximum concentration in the blood plasma is achieved after 1–16 hours, on average after 2–3 hours, after intramuscular administration — after 10–20 minutes. High concentrations of the drug are achieved in the blood, bile, liver, myocardium, lungs and kidneys. In synovial fluid, the concentration of diclofenac is 30% lower than in blood plasma, but is determined longer than in plasma. The volume of distribution is 0.2–0.55 l/kg. After oral administration, diclofenac undergoes pronounced first-pass metabolism, only 35–70% of the absorbed active substance enters the systemic circulation unchanged. Penetrates well into tissue, synovial fluid and breast milk. The half-life is practically independent of liver and kidney function and is approximately 2 hours, from synovial fluid - 3-6 hours. Metabolized in the liver (by hydroxylation and conjugation). About 70% is excreted in the urine in the form of pharmacologically inactive metabolites and approximately 30% in feces. Binding to plasma proteins is almost 99%. Diclak ID tablets are two-layer tablets with a combination of rapid (1/6 of the total) and gradual release (5/6 of the total) diclofenac sodium. This combination of effects ensures both a rapid onset of action and long-term circulation of the active substance in the systemic circulation and a therapeutic effect throughout the day.

Reviews

For the most part, reviews of Diclak gel and other forms of this drug are similar to each other: almost all patients note the high effectiveness of the drug. However, after stopping the course of treatment, the symptoms of the disease often return again. Therefore, like its analogues, Diklak is considered primarily as a means for symptomatic therapy.

To completely eliminate the disease, the patient usually requires a thorough examination and elimination of the cause that provoked the development of the pathological process.

Use of the drug Diclak

The dose of the drug is determined individually, depending on the patient’s age and the severity of the disease. The duration of the course should not exceed 3 weeks. Recommended doses for adults and adolescents over 15 years of age are 50–150 mg/day in 1–3 divided doses. The maximum daily dose of the drug is 150 mg. Diclak tablets should be taken after meals, without chewing and with a sufficient amount of liquid (1/2–1 glass of water). Adults are prescribed 1 tablet of Diclac ID modified release (75 or 150 mg) once a day. The modified-release tablet should be taken after or during meals without chewing, with sufficient liquid (1/2 to 1 glass of water). In acute conditions or exacerbations of chronic processes, adults are prescribed IM at a dose of 75 mg once a day, and in some cases administration is allowed 2 times a day. If the symptoms of the disease are most pronounced during the night or in the morning, Diclak ID should be used in the evening.

Composition and release form:

Enteric tablets 50 mg (20 tablets in a blister).
Diclofenac sodium modified release tablets 75; 150 mg (blister contains 20 or 100 tablets). Double-layer tablets (pink/white) round, flat, smooth, with beveled edges and bevels on both sides.

Solution for injection in ampoules of 3 ml (25 mg in 1 ampoule). There are 5 ampoules in a box.

Diclac tablets:

Active substance: diclofenac sodium.
Other components: lactose monohydrate, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, corn starch, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, triethyl citrate, eudragit L 30 D, talc, titanium dioxide (E171), yellow iron oxide (E172).

Diclak – solution for injection:

Active substance: diclofenac sodium.
Other components: benzyl alcohol, mannitol, n-acetylcysteine, propylene glycol, sodium hydroxide, water for injection.

Diklak ID:

Active substance: diclofenac sodium (1 75 mg modified-release tablet contains 62.5 mg sustained-release diclofenac sodium and 12.5 mg immediate-release diclofenac sodium; 1 150 mg modified-release tablet contains 125 mg sustained-release diclofenac sodium and 25 mg sodium diclofenac immediate release).
Other components: lactose monohydrate, methylhydroxypropylcellulose, microcrystalline cellulose, calcium hydrogen phosphate dihydrate, corn starch, sodium starch glycolate, colloidal silicon oxide, magnesium stearate, red iron oxide (E 172).

Side effects of the drug Diclak

Mainly dose dependent and vary significantly between individuals. The risk of gastrointestinal complications (gastritis, erosion, ulcers, bleeding) especially depends on the dose and duration of use. In isolated cases, the development of pancreatitis has been reported. The most likely symptoms are nausea, vomiting, diarrhea and gastrointestinal bleeding, which in some cases can lead to anemia. In some cases, manifestations of dyspepsia, intestinal spasms, anorexia, as well as the development of gastrointestinal ulcers (with the possibility of bleeding and perforation) are possible; Melena or bloody diarrhea rarely occurs. The patient should be informed of the need to stop treatment and urgently consult a doctor if the above phenomena occur. There are isolated reports of the development of stomatitis, glossitis, damage to the esophagus, disorders of the lower gastrointestinal tract (in particular, the manifestation of Crohn's disease, ulcerative colitis), constipation, and the development of diaphragmatic-intestinal strictures. In rare cases, hematopoietic disorders may occur (anemia, leukopenia, agranulocytosis, thrombocytopenia); their first manifestations may be fever, sore throat, flu-like symptoms, asthenia, nosebleeds, and skin hemorrhages. In some cases, the development of allergic vasculitis and hemolytic anemia was observed. Rarely, hypersensitivity reactions may occur, such as skin rashes and itching, urticaria or alopecia. In some cases, bullous exanthema, eczema, erythema, photosensitivity, purpura (including allergic purpura) and severe skin reactions (Stevens-Johnson syndrome, Lyell's syndrome) may occur. In some cases, the development of tachycardia, chest pain and increased blood pressure has been reported. Sometimes there may be an increase in the activity of serum transaminases. In some cases, liver damage is possible (hepatitis with or without jaundice, sometimes with a fulminant course, even without prodromal symptoms). Therefore, liver function indicators should be monitored during prolonged use of the drug. Isolated cases of allergic pneumonia have been observed. Occasionally, it is possible to develop disorders of the central nervous system, in particular headache, agitation, irritability, weakness, drowsiness and dizziness. It is also possible to develop disturbances in sensitivity, in particular tactile or taste, vision (blurred vision or diplopia), tinnitus and reversible hearing impairment, memory impairment, disorientation, muscle twitching, anxiety, nightmares, tremors, depression and psychotic reactions. Rarely, peripheral edema may occur, especially in patients with high blood pressure or impaired renal function. Also, rarely, damage to kidney tissue may occur with manifestations of acute renal failure, proteinuria and/or hematuria. In some cases, nephrotic syndrome may develop. Severe allergic reactions may develop. They can manifest as angioedema of the face, tongue and inner surface of the larynx with narrowing of the airways, impaired respiratory function, and, in particular, asthmatic attacks, tachycardia, decreased blood pressure, and shock. If one of these symptoms, which are possible during the first use of the drug, appears, adequate emergency therapy should be prescribed. In some cases, symptoms of aseptic meningitis may occur, such as neck muscle tension, fever or loss of consciousness. Patients with autoimmune diseases (systemic lupus erythematosus, collagenosis) are prone to such reactions.

Price, where to buy

The price of Diklak gel is approximately 200 rubles per 50 gram tube. The price of ointment for a tube with a capacity of 100 grams averages 290-300 rubles.

The cost of the drug in the form of rectal suppositories is from 90 to 100 rubles. The price of Diklak tablets starts at approximately 65 rubles per pack of 10 pieces.

Online pharmacies in RussiaRussia
Online pharmacies in UkraineUkraine

ZdravCity

Diklak gel 5% 50g Salutas Pharma GmbH
RUB 276 order
Diclak gel 5% 100gSalutas Pharma GmbH
RUB 391 order

Pharmacy Dialogue

Diclak gel (tube 5% 50g)Salutas Pharma GmbH
RUB 263 order
Diclak gel (tube 5% 100g)Salutas Pharma GmbH
RUR 378 order

Pharmacy24

Diklak 5% 100 g gel Salutas Pharma GmbH, Nimechchina
200 UAH.order
Diklak ID 150 mg N20 tablets Salutas Pharma GmbH, Nimecchina / Lek S.A. Poland
158 UAH order
Diclak 75 mg/3 ml N5 injection solution Lek pharmaceutical company d.d., Slovenia
90 UAH order
Diklak ID 75 mg No. 20 tablets Salutas Pharma GmbH, Nimechchina
98 UAH order
Diklak ID 150 mg No. 100 tablets Salutas Pharma GmbH, Nimecchina / Lek S.A. Poland
746 UAH order
Read also: Instructions for use of DIAZEPAM 2 mg, 5 mg, 10 mg

Special instructions for the use of Diclak

Diclofenac can be used only after a thorough assessment of the risk/benefit ratio in the following cases: in the first and second trimesters of pregnancy, with porphyria, systemic lupus erythematosus, collagenosis. Careful medical observation is necessary in case of a history of gastrointestinal disorders, peptic ulcers or inflammatory bowel diseases (ulcerative colitis, Crohn's disease); hypertension (arterial hypertension) and/or heart failure; history of kidney disease; severe liver dysfunction; in elderly patients; immediately after major surgical interventions; in patients with coagulation disorders; in patients with fever, nasal polyps or COPD, as well as hypersensitivity to other NSAIDs. Since the use of diclofenac sodium may cause side effects from the central nervous system, in particular weakness and dizziness, the drug may have an adverse effect on the ability to drive a car and work with potentially dangerous equipment. This is especially pronounced when taking alcohol at the same time. 1 tablet contains less than 0.01 metabolic carbohydrate units.

Overdose

The typical picture of an overdose of diclofenac has not been described. If the dose recommended by the instructions is exceeded, the possibility cannot be excluded:

vomiting;
bleeding from the gastrointestinal tract ;
bowel disorders (in particular, diarrhea );
dizziness;
development of convulsive seizures;
headaches;
involuntary muscle contractions and twitching (so-called myoclonic spasms; this symptom is most often observed in children).

Diclofenac intoxication may cause symptoms of acute renal failure and liver .

As in cases of poisoning with other drugs from the group of non-steroidal anti-inflammatory drugs, treatment for diclofenac involves the appointment of a complex of supportive and symptomatic measures.

Such measures are necessary in cases where the patient:

blood pressure levels decrease ;
of renal failure occur ;
Various types of disorders of the gastrointestinal tract ;
respiratory function is weakened.

Specific measures involving the administration of detoxification therapy (for example, forced diuresis or hemosorption ) are considered inappropriate, since the active components of non-steroidal anti-inflammatory drugs are characterized by the ability to significantly bind to plasma proteins and undergo intensive metabolization.

When treated with Diclak gel, intoxication is considered an unlikely event, which is due to the low rates of systemic absorption of diclofenac after topical use of the drug.

In cases where the patient inadvertently swallowed a certain amount of gel, symptomatic treatment is prescribed, which involves taking sorbents, gastric and prescribing a set of measures used in the treatment of symptoms of poisoning with non-steroidal anti-inflammatory drugs.

Drug interactions Diclak

Diclofenac sodium may reduce the effectiveness of ACE inhibitors. In addition, their combined use may increase the risk of renal dysfunction. Medicines containing probenecid may slow down the excretion of diclofenac sodium. The combined use of diclofenac sodium and digoxin, phenytoin or lithium preparations may increase the concentration of these drugs in the blood plasma. Diclofenac sodium may reduce the effectiveness of diuretics or antihypertensive drugs. Concomitant use of diclofenac sodium and potassium-sparing diuretics may lead to hyperkalemia; in such cases, monitoring the level of potassium in the blood plasma is necessary. The combined use of diclofenac sodium and other NSAIDs or corticosteroids increases the risk of side effects from the gastrointestinal tract. The use of diclofenac sodium within 24 hours before or after taking methotrexate may lead to an increase in the concentration of methotrexate in the blood plasma and, accordingly, to the appearance of its toxic effects. NSAIDs may increase the nephrotoxicity of cyclosporine. In some cases, after the use of diclofenac sodium, changes in blood glucose levels are observed, requiring appropriate adjustment of the dose of antidiabetic agents.

Note!

The description of the drug Diklak on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use. Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug).

Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.